UPDATE: Piper Jaffray Raises PT to $118 on Edwards Lifesciences on Lower Risks Ahead

Piper Jaffray reiterated its Overweight rating on Edwards Lifesciences

and increases its price target on shares from $90 to $118. Piper Jaffray noted, "We are raising our price target on EW reflecting the reduction in risk inherent with the positive national coverage decision (NCD), positive FDA panel meeting on high-risk patients, and the removal of uncertainty related to the outcome of the Supreme Court decision on the Affordable Care Act (ACA)." Edwards Lifescience closed at $104.44 on Thursday.